Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?

 
• By Emily Hayes

Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Neurological

More from Therapy Areas